(Las Vegas, Nevada, United States)’ DelveInsight’s “Cutaneous T-Cell Lymphoma Pipeline Insight, 2023” report provides comprehensive insights about 25+ companies and 27+ pipeline drugs in Cutaneous T-Cell Lymphoma (CTCL) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Cutaneous T-cell Lymphoma Pipeline Report
-
Leading Cutaneous T-cell Lymphoma companies developing novel drug candidates to improve the Cutaneous T-cell Lymphoma treatment landscape include Soligenix, Elorac, Innate Pharma, Viridian Therapeutics, SorrentoTherapeutics, Bio-Path Holdings, Legend Biotech, Genzada Pharmaceuticals, and others.
-
Promising Cutaneous T-cell Lymphoma pipeline therapies in various stages of development include SGX301, Lacutamab, BNZ-1, and others.
Cutaneous T-cell Lymphoma Overview
Cutaneous T-cell lymphoma is a rare type of blood cancer. It begins in a type of white blood cell called the T-lymphocyte (T-cell). T-cells help prevent infections and other diseases. As odd as it sounds, most T-cells are found in our skin. That’s because our skin is the first line of defense against disease. The surface of an adult’s skin contains about 20 billion T-cells. That’s nearly twice as many T-cells as found in other parts of the body.Mycosis fungoides is the most common type of Cutaneous T- cell Lymphoma. This type tends to worsen very slowly. It can stay in its earliest stage, which often looks like a rash, for years. In this stage, the cancer is often difficult to diagnose because it tends to looks like eczema or psoriasis. These conditions are much more common than CTCL. Sézary syndrome is more aggressive. It can also look like eczema. Some people develop red and swollen skin over much of their body.
Discover more about the emerging Cutaneous T-cell Lymphoma drugs @ Cutaneous T-cell LymphomaTreatment Drugs
Cutaneous T-cell Lymphoma Pipeline Therapies and Key Companies
SGX301: Soligenix
SGX301 is a novel first-in-class photodynamic therapy utilizing safe, visible light for activation. The active ingredient in SGX301 is synthetic hypericin, a potent photosensitizer that is topically applied to skin lesions, is taken up by the malignant T-cells, and then activated by fluorescent light 16 to 24 hours later. Currently, it is in the Phase III stage of clinical trial evaluation to treat Cutaneous T-Cell Lymphoma
Lacutamab : Innate Pharma
Lacutamab (IPH4102) is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is currently in clinical trials for the treatment of cutaneous T-cell lymphoma (CTCL), an orphan disease. This group of rare cutaneous lymphomas of T lymphocytes has a poor prognosis with few efficacious and safe therapeutic options at advanced stages. KIR3DL2 is an inhibitory receptor of the KIR family, expressed by approximately 65% of patients across all CTCL subtypes and expressed by up to 90% of patients with certain aggressive CTCL subtypes, in particular, Sézary syndrome.
BNZ-1: Bioniz
BNZ-1 is a selective inhibitor of three members of the IL-2 family: IL-2, IL-9, and IL-15. The profile of BNZ-1 is promising as a long-term therapy capable of transforming the standard of care in CTCL as data implicates the dysregulation of IL-2/IL-9/IL-15 as responsible for disease pathology. Bioniz conducted a Phase 1/2 study in CTCL, in which BNZ-1 exhibited a substantial improvement in safety and efficacy relative to the standard of care. BNZ-1 has orphan drug designation in US and EU.
Scope of the Cutaneous T-cell Lymphoma Pipeline Report
-
Coverage: Global
-
Key Cutaneous T-cell Lymphoma Companies: Soligenix, Elorac, Innate Pharma, Viridian Therapeutics, SorrentoTherapeutics, Bio-Path Holdings, Legend Biotech, Genzada Pharmaceuticals, and others.
-
Key Cutaneous T-cell Lymphoma Pipeline Therapies: SGX301, Lacutamab, BNZ-1, and others
Find out more about the Cutaneous T-cell Lymphoma treatment options in development @ Cutaneous T-cell Lymphoma Clinical Trials
Table of Contents
1. Cutaneous T-cell Lymphoma Introduction
2. Cutaneous T-cell Lymphoma Executive Summary
3. Cutaneous T-cell Lymphoma Overview
4. Cutaneous T-cell Lymphoma Pipeline Therapeutics
5. Cutaneous T-cell Lymphoma Late-Stage Products (Phase III)
6. Cutaneous T-cell Lymphoma Mid-Stage Products (Phase II)
7. Cutaneous T-cell Lymphoma Early Stage Products (Phase I/II)
8. Cutaneous T-cell Lymphoma Preclinical Stage Products
9. Cutaneous T-cell Lymphoma Discovery Stage Products
10. Cutaneous T-cell Lymphoma Therapeutic Assessment
11. Cutaneous T-cell Lymphoma Inactive Products
12. Cutaneous T-cell Lymphoma Collaborations Assessment- Licensing / Partnering / Funding
13. Cutaneous T-cell Lymphoma Unmet Needs
14. Cutaneous T-cell Lymphoma Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services